Persistent risk for new, subsequent new and recurrent hepatocellular carcinoma despite successful anti-hepatitis B virus therapy and tumor ablation: The need for hepatitis B virus cure

doi:10.4254/wjh.v11.i1.65

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 11, Issue 1

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (8751)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-3) series, Tables (1-2) series.

Item

Count

PDF

482

WORD

247

HTML

4061

Figures (1-3)

359

Tables (1-2)

245

Sum=5394

Featured Article

The chart showing Browse series, Download series.

Item

Count

Browse

505

Download

673

Sum=1178

Publishing Process of This Article

Item

Count

Browse

906

Download

1273

Sum=2179

Jan 27, 2019 (publication date) through Nov 22, 2024

Times Cited of This Article

Times Cited (12)

Journal Information of This Article

Publication Name

World Journal of Hepatology

ISSN

1948-5182

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Minireviews

World J Hepatol. Jan 27, 2019; 11(1): 65-73
Published online Jan 27, 2019. doi: 10.4254/wjh.v11.i1.65

Open in New Tab Full Size Figure Download Figure

Figure 1 Hepatitis B replication life cycle.

Open in New Tab Full Size Figure Download Figure

Figure 2 Hepatocellular carcinoma in three patients with chronic hepatitis B[18]. HCC: Hepatocellular carcinoma; HBV: Hepatitis B virus.

Open in New Tab Full Size Figure Download Figure

Figure 3 Persistent risk for recurrent hepatocellular carcinoma in a patient with chronic hepatitis B[18]. HCC: Hepatocellular carcinoma; HBV: Hepatitis B virus; MRI: Magnetic resonance imaging; TACE: Transarterial chemoembolization; RFA: Radiofrequency ablation.

Citation: Shinn BJ, Martin A, Coben RM, Conn MI, Prieto J, Kroop H, DiMarino AJ, Hann HW. Persistent risk for new, subsequent new and recurrent hepatocellular carcinoma despite successful anti-hepatitis B virus therapy and tumor ablation: The need for hepatitis B virus cure. World J Hepatol 2019; 11(1): 65-73
URL: https://www.wjgnet.com/1948-5182/full/v11/i1/65.htm
DOI: https://dx.doi.org/10.4254/wjh.v11.i1.65